Mereo Biopharma, established in London in 2015, specializes in acquiring and advancing late-stage drug candidates from larger pharmaceutical companies. These candidates, often overlooked due to resource constraints, target rare and specialized diseases with significant unmet medical needs. Mereo's strategy involves rapidly progressing these assets through clinical development, either by partnering or divesting them, or directly commercializing them, particularly in orphan disease indications. The company combines operational efficiency with financial resources, leveraging a unique partnership with a leading global CRO, ICON, to conduct comprehensive clinical studies. Mereo's focus is on transforming the lives of patients worldwide by developing innovative medicines that can significantly improve their quality of life.
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in the discovery and development of innovative therapeutics aimed at addressing the biological mechanisms that drive cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody targeting Delta-like ligand 4 and vascular endothelial growth factor, which has completed early-phase clinical trials for various solid tumors. Another key candidate, Etigilimab, is an anti-TIGIT monoclonal antibody currently undergoing Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed is also engaged in strategic partnerships aimed at the development of novel small molecule therapeutics and biologics targeting cancer stem cells and the Wnt signaling pathway. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.